Loading...
| Name | Option type | Quality (1-5)↓ | Topics | Created | |
|---|---|---|---|---|---|
Iqirvo sales performance in Q3 2024  | Binary | 5 | 7 months ago | ||
Iqirvo receives EMA approval by June 2025 | Binary | 5 | 7 months ago | ||
Leading drug for primary biliary cholangitis by June 2025 | Categorical | 5 | 7 months ago | ||
Ipsen vs Genfit stock performance by December 2024 | Categorical | 5 | 7 months ago | ||
Iqirvo first year sales figures | Categorical | 4 | 7 months ago | ||
Iqirvo market share in primary biliary cholangitis by June 2025 | Binary | 3 | 7 months ago |